NOZINAN Levomepromazine Maleate 25mg Tablet 1's
RXDRUG-DR-9226-1pc
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Nozinan
Full Details
Dosage Strength
25 mg
Drug Ingredients
- Levomepromazine
Drug Packaging
Tablet 1's
Generic Name
Levomepromazine Maleate
Dosage Form
Tablet
Registration Number
DR-9226
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Management of terminal illness particularly in those marked by restlessness, anxiety, agitation, emotional disturbance, pain, nausea and vomiting.
In psychiatry, especially in schizophrenia when it is desirable to reduce psychomotor activity.
In psychiatry, especially in schizophrenia when it is desirable to reduce psychomotor activity.
Dosage/Direction for Use
Adults: Ambulatory Patients: Initially, the total daily oral dose should not exceed 25-50 mg, usually divided into 3 doses; a larger portion of the dosage may be taken at bedtime to minimize diurnal sedation. The dosage is then gradually increased to the most effective level compatible with sedation and other side effects.
Bed Patients: Initially, the total daily oral dosage may be 100-200 mg, usually divided into 3 doses, gradually increased to 1 g daily if necessary. When the patient is stable, attempts should be made to reduce the dosage to an adequate maintenance level.
Children: Children are very susceptible to the hypotensive and soporific effects of levomepromazine. It is advised that a total daily oral dosage of 40 mg should not be exceeded. The average effective daily intake for a 10-year old is 15-20 mg.
Bed Patients: Initially, the total daily oral dosage may be 100-200 mg, usually divided into 3 doses, gradually increased to 1 g daily if necessary. When the patient is stable, attempts should be made to reduce the dosage to an adequate maintenance level.
Children: Children are very susceptible to the hypotensive and soporific effects of levomepromazine. It is advised that a total daily oral dosage of 40 mg should not be exceeded. The average effective daily intake for a 10-year old is 15-20 mg.
Overdosage
Symptoms: Symptoms of levomepromazine overdosage include drowsiness or loss of consciousness, hypotension, tachycardia, electrocardiogram (ECG) changes, ventricular arrythmias and hypothermia. Severe extrapyramidal dyskinesias may occur.
Treatment: If the patient is seen sufficiently soon (up to 6 hrs) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis in unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive.
Treatment: If the patient is seen sufficiently soon (up to 6 hrs) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis in unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive.
Contraindications
There are no absolute contraindications to the use of Nozinan in terminal care.
Special Precautions
Nozinan should be avoided or used with caution in patients with liver dysfunction or cardiac disease.
The hypotensive effects of Nozinan should be taken into account when it is administered to patients with cardiac disease and in the elderly or debilitated. Patients receiving large initial doses should be kept in bed. Avoid alcoholic drinks.
Effects on the Ability to Drive or Operate Machinery: Nozinan may cause drowsiness, disorientation, confusion or excessive hypotension which may affect patient's ability to drive or operate machinery.
Use in pregnancy: Safety in pregnancy has not been established.
Use in the elderly: It is not advisable to give Nozinan to ambulatory patients >50 years unless the risk of hypotensive reaction has been assessed.
The hypotensive effects of Nozinan should be taken into account when it is administered to patients with cardiac disease and in the elderly or debilitated. Patients receiving large initial doses should be kept in bed. Avoid alcoholic drinks.
Effects on the Ability to Drive or Operate Machinery: Nozinan may cause drowsiness, disorientation, confusion or excessive hypotension which may affect patient's ability to drive or operate machinery.
Use in pregnancy: Safety in pregnancy has not been established.
Use in the elderly: It is not advisable to give Nozinan to ambulatory patients >50 years unless the risk of hypotensive reaction has been assessed.
Use In Pregnancy & Lactation
Use in pregnancy: Safety in pregnancy has not been established.
Adverse Reactions
Somnolence, asthenia, dry mouth, hypotension, agranulocytosis, photosensitivity, allergic skin reactions. Parkinson-like reactions in high doses.
Drug Interactions
Simultaneous administration of desferrioxamine and prochlorperazine has been observed to induce a transient metabolic encephalopathy characterized by loss of consciousness for 48-72 hrs. It is possible that this may occur with levomepromazine since it shares many of the pharmacological activities of prochlorperazine. Adrenaline must not be used in patients overdosed with neuroleptics.
Storage
Store at temperatures not exceeding 30°C.
Action
Nozinan possesses antiemetic, antihistamine and antiadrenaline activity and exhibits a strong sedative effect.
Pharmacology: Nozinan potentiates the action of other central nervous system (CNS) depressants but may be given in conjunction with appropriately modified doses of narcotic analgesics in the management of severe pain. Nozinan does not significantly depress respiration and is particularly useful where pulmonary reserve is low.
Pharmacokinetics: Maximum serum concentrations are achieved in 2-3 hrs. Excretion is slow, with a t½ of about 30 min. It is eliminated via urine and feces.
Pharmacology: Nozinan potentiates the action of other central nervous system (CNS) depressants but may be given in conjunction with appropriately modified doses of narcotic analgesics in the management of severe pain. Nozinan does not significantly depress respiration and is particularly useful where pulmonary reserve is low.
Pharmacokinetics: Maximum serum concentrations are achieved in 2-3 hrs. Excretion is slow, with a t½ of about 30 min. It is eliminated via urine and feces.
MedsGo Class
Antipsychotics
Please sign in so that we can notify you about a reply